US1890541097 - Common Stock

Taking everything into account, **CLX** scores **4** out of 10 in our fundamental rating. **CLX** was compared to 12 industry peers in the **Household Products** industry. There are concerns on the financial health of **CLX** while its profitability can be described as average. While showing a medium growth rate, **CLX** is valued expensive at the moment.

In the past year **CLX** had a positive cash flow from operations.

In the past 5 years **CLX** has always been profitable.

In the past 5 years **CLX** always reported a positive cash flow from operatings.

Looking at the **Return On Assets**, with a value of **6.49%**, **CLX** is in line with its industry, outperforming **50.00%** of the companies in the same industry.

With an excellent **Return On Equity** value of **595.00%**, **CLX** belongs to the best of the industry, outperforming **91.67%** of the companies in the same industry.

The **Return On Invested Capital** of **CLX** (**21.32%**) is better than **75.00%** of its industry peers.

Measured over the past 3 years, the **Average Return On Invested Capital** for **CLX** is in line with the industry average of **15.29%**.

The 3 year average ROIC (**13.49%**) for **CLX** is below the current ROIC(**21.32%**), indicating increased profibility in the last year.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 6.49% | ||

ROE | 595% | ||

ROIC | 21.32% |

ROA(3y)4.96%

ROA(5y)8.24%

ROE(3y)78.73%

ROE(5y)102.47%

ROIC(3y)13.49%

ROIC(5y)15.84%

The **Profit Margin** of **CLX** (**4.78%**) is comparable to the rest of the industry.

In the last couple of years the **Profit Margin** of **CLX** has declined.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 15.88% | ||

PM (TTM) | 4.78% | ||

GM | 44.56% |

OM growth 3Y-7.85%

OM growth 5Y-6.18%

PM growth 3Y-25.82%

PM growth 5Y-21.44%

GM growth 3Y-0.28%

GM growth 5Y-0.32%

The number of shares outstanding for **CLX** has been increased compared to 1 year ago.

The number of shares outstanding for **CLX** has been reduced compared to 5 years ago.

Compared to 1 year ago, **CLX** has a worse debt to assets ratio.

Looking at the **Altman-Z score**, with a value of **4.33**, **CLX** is in line with its industry, outperforming **58.33%** of the companies in the same industry.

The Debt to FCF ratio of **CLX** is **3.72**, which is a good value as it means it would take **CLX**, **3.72** years of fcf income to pay off all of its debts.

A Debt/Equity ratio of **41.43** is on the high side and indicates that **CLX** has dependencies on debt financing.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 41.43 | ||

Debt/FCF | 3.72 | ||

Altman-Z | 4.33 |

ROIC/WACC2.58

WACC8.27%

The **Current ratio** of **CLX** (**1.00**) is worse than **75.00%** of its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1 | ||

Quick Ratio | 0.62 |

The **Earnings Per Share** has grown by an impressive **62.37%** over the past year.

The **Earnings Per Share** has been decreasing by **-0.51%** on average over the past years.

The **Revenue** has been growing slightly by **2.68%** on average over the past years.

EPS 1Y (TTM)62.37%

EPS 3Y-7.55%

EPS 5Y-0.51%

EPS Q2Q%279.59%

Revenue 1Y (TTM)6.17%

Revenue growth 3Y-1.14%

Revenue growth 5Y2.68%

Sales Q2Q%27.13%

The **Revenue** is expected to grow by **3.65%** on average over the next years.

EPS Next Y11.94%

EPS Next 2Y9.12%

EPS Next 3Y7.83%

EPS Next 5Y7.27%

Revenue Next Year-1.32%

Revenue Next 2Y0.54%

Revenue Next 3Y1.33%

Revenue Next 5Y3.65%

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

A **Price/Earnings** ratio of **21.88** indicates a rather expensive valuation of **CLX**.

The rest of the industry has a similar **Price/Earnings** ratio as **CLX**.

Compared to an average S&P500 **Price/Earnings** ratio of **29.17**, **CLX** is valued a bit cheaper.

Based on the **Price/Forward Earnings** ratio of **22.44**, the valuation of **CLX** can be described as rather expensive.

The rest of the industry has a similar **Price/Forward Earnings** ratio as **CLX**.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 21.88 | ||

Fwd PE | 22.44 |

The rest of the industry has a similar **Enterprise Value to EBITDA** ratio as **CLX**.

Based on the **Price/Free Cash Flow** ratio, **CLX** is valued a bit more expensive than 75.00% of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 30.56 | ||

EV/EBITDA | 16.02 |

The high **PEG Ratio(NY)**, which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.

The decent profitability rating of **CLX** may justify a higher PE ratio.

PEG (NY)1.83

PEG (5Y)N/A

EPS Next 2Y9.12%

EPS Next 3Y7.83%

Compared to an average S&P500 **Dividend Yield** of **2.21**, **CLX** pays a bit more dividend than the S&P500 average.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 3% |

The dividend of **CLX** has a limited annual growth rate of **4.43%**.

Dividend Growth(5Y)4.43%

Div Incr Years33

Div Non Decr Years33

DP167.23%

EPS Next 2Y9.12%

EPS Next 3Y7.83%

**CLOROX COMPANY**

NYSE:CLX (11/8/2024, 8:04:00 PM)

After market: 165.2 +0.04 (+0.02%)**165.16**

**+2.39 (+1.47%) **

Chartmill FA Rating

GICS SectorConsumer Staples

GICS IndustryGroupHousehold & Personal Products

GICS IndustryHousehold Products

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap20.44B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 3% |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 21.88 | ||

Fwd PE | 22.44 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)1.83

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 6.49% | ||

ROE | 595% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 15.88% | ||

PM (TTM) | 4.78% | ||

GM | 44.56% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover1.36

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 41.43 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 1 | ||

Quick Ratio | 0.62 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)62.37%

EPS 3Y-7.55%

EPS 5Y

EPS Q2Q%

EPS Next Y11.94%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)6.17%

Revenue growth 3Y-1.14%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y